47results about How to "Rapid symptoms" patented technology

The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I)

wherein R¹ is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R² is an optionally substituted C_6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R³ and R⁴ are each a hydrogen atom, or one of R³ and R⁴ is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R⁵ is an alkyl group or a salt thereof.

Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C_max) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.

The invention provides a preparation method of a compound Chinese traditional medicine preparation used for treating AIDS; the preparation is prepared into a pill by the following raw materials: rhinoceros horn, royal jelly, pilose antler, ginseng, salvia miltiorrhiza, antelope horn 5, radix codonopsitis, radix adenophorea, brown sugar, honey, Chinese caterpillar fungus, black sesame oil, and so on; a decoction is prepared by the following raw materials: spine date seed, wild chrysanthemum flower, atractylodes rhizome, liquorice, Chinese goldthread, pseudoginseng, fumitory, great burdock achene, bitter orange, fritillaria, polygalae, Chinese cynomorium, and so on; a medicated bath preparation is prepared by the raw materials of radix asparagi, vervain, dendrobe, rehmanniae radix, glossy privet fruit, pagoda flower, dried orange peel, magnolia officinalis, asiatic plantain seed, dodder, oyster, centipede, and so on. The pill and the decoction are taken orally and the bath preparation is heating for external bathing; the unconventional treatment method of taking the improvement of autoimmune function and metabolism as the priority and the external and internal treatment of the decoction as the auxiliary is implemented for treating, relatively ideal curative effect is achieved, the effective rate reaches over 80 percent, and the invention provided a effective new path for the world-wide stubborn ill of AIDS.

The invention relates to gel with anti-inflammation, anti-pruritus and sterilization effects, and belongs to the field of medicines. The gel is mainly applied to pediatric pruritic dermatosis, and can be used in different forms such as a therapeutic medicament and/or a sterilizer, a health care product, a sanitary product and the like for adjunctive therapy or for different purposes. The invention provides brand-new gel, wherein the gel is prepared by adding pharmaceutically acceptable minor ingredients into the following raw materials in parts by weight: 10 to 20 parts of lonicera japonica (lonicera confusa), 4 to 12 parts of belvedere fruit, 6 to 14 parts of astragalus mongholicus, 1 to 4 parts of lithospermum purpurocaeruleum, 8 to 16 parts of cortex dictamni, 1 to 4 parts of mint, 0.001 to 2 parts of borneol, 1 to 4 parts of cicada slough, 8 to 16 parts of talc, 1 to 4 parts of licorice and 0.1 to 2 parts of honey. By the gel, the effects of dispelling wind, clearing heat, cooling blood, resolving toxin, removing dampness, relieving itching, removing impurities and protecting skin can be effectively achieved; and the gel is particularly applied to the pediatric pruritic dermatosis such as pediatric papular urticaria, miliaria, dermatitis aestivale, diaper dermatitis and eczema.

The invention discloses a derivant of establishing a rheumatoid arthritis animal model, and preparation and application thereof; the derivant comprises II type collagen, aluminium hydroxide, glacial acetic acid and complete freund adjuvant; the derivant can successfully form the rheumatoid arthritis animal model, can substantially boost immunization reaction, can keep arthritis symptom to last for a longer time, so clinic symptom and pathology change of the animal model can be more close to real rheumatoid arthritis; the preparation method of the derivant is simple in operation, and convenient for promotion and application; the derivant is used for establishing the rheumatoid arthritis animal model, is simple and safe in realization, good in stable reliability, high in molding success rate, and has excellent application prospect.

The invention discloses a facial palsy rectify patch and a treatment method. The rectify patch consists of medicines and the patches for bearing the medicines. The medicines are made of master medicines and auxiliary medicines. The master medicines comprise the medicines as follows: radix astragali, cassia twig, gambir plant, red peony, salvia miltiorrhiza, szechuan lovage rhizome, kudzuvine root, great burdock achene, earthworm, weeping forsythiae capsule, baical skullcap root, honeysuckle flower, medcinal evodia fruit, zedoary root, turmeric, divaricate saposhnikovia root, magnetite, Bungarus multicinctus, Chinese sage herb, simpleleaf shrub chastetree fruit and paris polyphylla; while the auxiliary medicines comprise one milliliter of laurocapam with a concentration of one percent. The invention can make full use of the Chinese medicine effect and has quick medical effect and obvious efficacy; the medicine is stuck at the joints, channels and collaterals on the surface corresponding to the human body viscera so as to exert a certain positive excitation, so that the nerves can change during the process of energy conversion and information coding; the invention also can activate, enhance, decrease or deactivate some enzymes inside the cell, thereby promoting the body own solution and the recovery ability through the nerves and the internal secretion so as to cure diseases and eliminate symptoms.

The invention discloses a bone hyperplasia plaster, which is prepared from the following raw materials in parts by weight: clematis 10-20, frankincense 2-5, myrrh 2-5, Xu Changqing 10-20, safflower 10 -20, camphor 2-5, borneol 2-5, Chuanwu 5-10, kudzu root 5-10. The invention also discloses a preparation method of the plaster. According to clinical tests, the plaster has the advantages of rapid symptom improvement, high cure rate and low recurrence rate after healing.

Estramustine phosphate is an anti-mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administered at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.

Asthma is an inflammatory disease of the airways in the lungs and bronchial tubes, the lower airway, that impairs breathing, causes wheezing, coughing and excess mucus and phlegm production. Asthma is the source of about one-fourth of all emergency room admissions. Throat lozenges and orally-retained liquids, such as syrups, containing magnesium are used in the invention to rapidly terminate asthma attacks and prevent asthma attacks. Magnesium lozenges and magnesium orally-retained liquids are effective in asthma rescue. Treatment of asthma with orally-retained magnesium, an essential human nutrient, is much safer than treatment by drugs yet they appear as effective as current drugs. An added benefit from magnesium treatment is relaxation. A preferred composition is 100 mg of magnesium from 400 mg magnesium chloride in a 4-gram lozenge. Magnesium lozenges or orally-retained liquids are administered as needed to treat asthma attacks or prevent incipient asthma attacks. Throat lozenges and orally-retained liquids of any pharmaceutically acceptable composition containing any pharmaceutically acceptable compound of magnesium are disclosed and claimed as effective in the treatment and prevention of asthma.

A device/system and a method of treating enlarged prostate and other urologic abnormalities are presented. A combined treatment is performed with several interstitial coagulating probes and an ablating fiber. Tissue vaporization is minimized by the denaturalizing effect of interstitial coagulative fibers. In a single device, multiple delivery systems achieve optimal tissue ablation/coagulation; a non-laser source like microwave energy coagulates tissue and a laser source ablates tissue. Another device comprises two or more laser sources with adjustable wavelengths controllable by physician as to ablative, coagulative, and tissue penetration needs. Continuous, semi-continuous, pulsed wave, or combinations are useful. In another embodiment, optical fiber has a central core for transmitting laser radiation, and a cladding layer about the core that may further transmit other laser radiation of a different or a same wavelength as the core. Fibers may have a side-firing distal end, a radial firing end, or an off-axis firing end. Feedback controls can be used. In general coagulative irradiation can use a radiofrequency or other radiant thermal source.

An imidazole compound represented by the formula (I), a salt thereof and a compound of the formula (V), which is one of the intermediates thereof. wherein each symbol is as defined in the present specification. The compound of the present invention shows a superior anti-ulcer activity, a gastric acid secretion inhibitory action, a mucosa-protecting action, an anti-Helicobacter pylori action and the like. Since it shows low toxicity, the compound is useful as a pharmaceutical product.

The invention discloses a pharmaceutical composition for treating pharyngitis and laryngitis, which contains Iris tectorum Maxim. extract flavones as the active ingredient, and pharmaceutically acceptable adjuvant or supplementary constituents, wherein the content of the extract flavones is greater than 55% calculated by Tectoridin C22H22O11. The effective constituents being Tectoridin, Tectoridin A, Tectorigenin, and wild Tectorigenin, the four ingredients have synergic action.

The invention belongs to the field of traditional Chinese medicines and healthcare foods, and particularly relates to a ganoderma lucidum origin-consolidating composition and medicinal liquor and a preparation method and application thereof. The invention aims at providing a brand new composition for nourishing kidney, tonifying spleen and qi and increasing essence, which takes ganoderma lucidum as a main component and is obtained by matching with multiple traditional Chinese medicines. The composition consists of ganoderma lucidum, hericium erinaceus, fructus lycii, rhizoma polygonati, fructus rubi, oyster, rhizoma dioscoreae, poria cocos, fructus crataegi, fructus hordei germinatus, endothelium corneum gigeriae galli, phyllanthus emblica, herba taraxaci, lophatherum gracile, fructus gardeniae and liquorice. The invention also provides the ganoderma lucidum origin-consolidating medicinal liquor which is prepared by adopting the following steps: adding water into the composition according to a conventional method and decocting; combining and concentrating; and adding white spirit, stevioside and osmanthus fragrans essence and mixing to obtain the medicinal liquor. By direct drinking, the medicinal liquor has the effects of nourishing kidney, tonifying spleen and qi and increasing essence.

The invention discloses an external composition for treating the bone disease and a preparation method of the external composition. The external composition is prepared from the following bulk pharmaceutical chemicals in parts by weight: 18-25 parts of chinese angelica, 8-13 parts of safflower, 14-18 parts of rhizoma chuanxiong, 18-25 parts of drynaria total flavonoids, 18-25 parts of clematis chinensis, 18-25 parts of radix astragali seu hedysari, 18-25 parts of clematis chinensis, 18-25 parts of radix notoginseng, 18-25 parts of corydalis yanhusuo, 3-8 parts of olibanum, 3-8 parts of myrrh,3-8 parts of borneol, 14-18 parts of paniculate swallowwort root, 4-10 parts of camphor, 8-13 parts of radix aconit and 15-20 parts of eucommia ulmoides. The preparation method comprises the steps that after all the bulk pharmaceutical chemicals are mixed uniformly, then soaked for 2-4 h and fried through high heat for 3-5 h, supernatant liquid is taken and concentrated, and base materials are added to make a paste. The external composition for treating the bone disease has the characteristics of pain relieving and swelling, rapid improvement of symptoms, high cure rate and low recurrence rateafter healing for various types of the bone disease caused by wind, cold and wetness.

The invention relates to the field of drug carriers, in particular to a bone-targeted nanoparticle delivery system and a preparation method thereof. The bone-targeted nanoparticle delivery system comprises nanoparticles and bone-targeted functional components. The nanoparticles are monolayer vesicles internally wrapped with pharmaceutical active ingredients, the vesicle membranes of the monolayervesicles are composed of degradable polymers and polyvinyl alcohol, the vesicle membranes are cuttaged with dithiosuccinimide-octyl diacid ester, and the nanoparticles are in conjugated combination with the bone-targeted functional components through the dithiosuccinimide-octyl diacid ester. According to the bone-targeted nanoparticle delivery system, as the monolayer vesicles are wrapped with thepharmaceutical active ingredients, greater drug carrying capacity is achieved, in addition, through detection, stability of vitro release test is good, and drug release is controllable.